BRPI0402630A - processo de obtenção de nova vacina pertussis celular - Google Patents

processo de obtenção de nova vacina pertussis celular

Info

Publication number
BRPI0402630A
BRPI0402630A BRPI0402630-6A BRPI0402630A BRPI0402630A BR PI0402630 A BRPI0402630 A BR PI0402630A BR PI0402630 A BRPI0402630 A BR PI0402630A BR PI0402630 A BRPI0402630 A BR PI0402630A
Authority
BR
Brazil
Prior art keywords
obtaining new
pertussis vaccine
cellular pertussis
new cellular
vaccine
Prior art date
Application number
BRPI0402630-6A
Other languages
English (en)
Inventor
Isaias Raw
Flavia Saldanha Kubrusly
Waldely De Oliveira Dias
Maria Izabel Esteves
Noemi Furuyama
Denise Silvina Piccini Horton
Ednilse Leme
Wagner Quintilio
Maria Aparecida Sakauchi
Sally Muller Affonso Prado
Elizabeth Mendes
Hisako Gondo Higashi
Original Assignee
Fundacao Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Butantan filed Critical Fundacao Butantan
Priority to BRPI0402630A priority Critical patent/BRPI0402630B8/pt
Priority to EP04761533A priority patent/EP1809323A1/en
Priority to PCT/BR2004/000172 priority patent/WO2006002502A1/en
Publication of BRPI0402630A publication Critical patent/BRPI0402630A/pt
Publication of BRPI0402630B1 publication Critical patent/BRPI0402630B1/pt
Publication of BRPI0402630B8 publication Critical patent/BRPI0402630B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Abstract

"PROCESSO DE OBTENçãO DE NOVA VACINA PERTUSSIS CELULAR". Que prevê a utilização de células de Bordetella pertussis, obtidas por cultivo em fermentador, destoxificadas por formaldeído, que após tratamento com solvente orgânico originam preparações vacinais menos tóxicas e tão potentes quanto a vacina pertussis celular tradicional.
BRPI0402630A 2004-07-05 2004-07-05 processo de obtenção de vacina pertussis celular menos reatogênica BRPI0402630B8 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BRPI0402630A BRPI0402630B8 (pt) 2004-07-05 2004-07-05 processo de obtenção de vacina pertussis celular menos reatogênica
EP04761533A EP1809323A1 (en) 2004-07-05 2004-09-13 Process for obtention of new cellular pertussis vaccine
PCT/BR2004/000172 WO2006002502A1 (en) 2004-07-05 2004-09-13 Process for obtention of new cellular pertussis vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0402630A BRPI0402630B8 (pt) 2004-07-05 2004-07-05 processo de obtenção de vacina pertussis celular menos reatogênica

Publications (3)

Publication Number Publication Date
BRPI0402630A true BRPI0402630A (pt) 2006-08-01
BRPI0402630B1 BRPI0402630B1 (pt) 2019-12-10
BRPI0402630B8 BRPI0402630B8 (pt) 2021-05-25

Family

ID=36716698

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0402630A BRPI0402630B8 (pt) 2004-07-05 2004-07-05 processo de obtenção de vacina pertussis celular menos reatogênica

Country Status (3)

Country Link
EP (1) EP1809323A1 (pt)
BR (1) BRPI0402630B8 (pt)
WO (1) WO2006002502A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040806A2 (pt) * 2010-09-28 2012-04-05 Fundação Butantan Composições imunogênicas sinérgicas baseadas em antígenos proteicos combinados com antígeno celular pertussis e toxinas inativadas

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20160193322A1 (en) 2013-08-05 2016-07-07 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750925A (en) * 1980-09-12 1982-03-25 Takeda Chem Ind Ltd Preparation of pertussis toxoid
JP2706792B2 (ja) * 1988-11-29 1998-01-28 財団法人化学及血清療法研究所 百日咳毒素のトキソイド化法
DE69022106T2 (de) * 1989-04-28 1996-02-15 Sclavo Spa Pertussistoxin-Mutanten, dieselbe produzierende Bordetella-Stämme und ihre Verwendung als Vakzin gegen Pertussis.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040806A2 (pt) * 2010-09-28 2012-04-05 Fundação Butantan Composições imunogênicas sinérgicas baseadas em antígenos proteicos combinados com antígeno celular pertussis e toxinas inativadas
WO2012040806A3 (pt) * 2010-09-28 2012-07-19 Fundação Butantan Composições imunogênicas sinérgicas baseadas em antígenos proteicos combinados com antígeno celular pertussis e toxinas inativadas

Also Published As

Publication number Publication date
WO2006002502A1 (en) 2006-01-12
EP1809323A1 (en) 2007-07-25
BRPI0402630B1 (pt) 2019-12-10
BRPI0402630B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
HK1210627A1 (en) Preparing crude biological estracts using protease, suitable for preparing cdna cdna
DK1603663T3 (da) Keramisk nanofiltrationsmembran til anvendelse i organiske opløsningsmidler og fremgangsmåde til deres fremstilling
PA8629901A1 (es) Sintesis regioespecifica de derivados de 42-ester de rapamicina
MEP44608A (en) Methods for treating infectious disease exacerbated asthma
UY28731A1 (es) Compuestos quimicos
HRP20060418A2 (en) Material solubiliser reactor for hydrolysis and/or wet fermentation and waste treatment plant with such a solubiliser and reactor
ATE430797T1 (de) Vorrichtung und verfahren zur fermentativen herstellung biologisch wirksamer verbindungen
BRPI0402630A (pt) processo de obtenção de nova vacina pertussis celular
CR9472A (es) Derivados de aminoacidos
ECSP066275A (es) Piridinilanilidas
MEP56408A (en) Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
MX2009003533A (es) Composición farmacéutica que comprende derivado de fenilamidina y método para usar la composición farmacéutica en combinación con el aceite antifúngico.
TW200507867A (en) Extract of plant dendrobii caulis and preparing process thereof
EA200700272A1 (ru) Процесс чанового биовыщелачивания
TW200741339A (en) Resist composition and method of manufacturing resist composition
NO20064837L (no) Monoazofaregestoffer
DE602005013681D1 (de) Verfahren zur herstellung von escitalopram
BRPI0416274A (pt) método para produzir solução de amÈnio de ácido orgánico
AR014528A1 (es) Adn que comprende una secuencia de nucleotidos que se puede traducir a una proteina con actividad de invertasa, proteina derivada del adn que tieneactividad de invertasa pero que carece de actividad beta-fructofuranosidasa; metodo para producir adn y dicho metodo donde el adn es producido por una
CL2008002003A1 (es) Componente de vacuna anti-pertussis que comprende pertactina (prn) de proteina de membrana celular de bordetella pertussis; procedimiento simplificado para obtener prn con mas de un 90% de pureza.
ES2530760T3 (es) Peptidasas de basidiomicetos
WO2006011416A8 (ja) 環境浄化方法および環境浄化剤
TWI264571B (en) Gel, polarizer laminated by the gel and fabrication method thereof
ATE517109T1 (de) Isopropanol-wasser-solvat von olanzapin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2677 DE 26-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.